VLX 1005
Alternative Names: ML-355; VLX-1005Latest Information Update: 09 Oct 2023
At a glance
- Originator Eastern Virginia Medical School; National Institutes of Health (USA); Thomas Jefferson University; University of California
- Developer University of Michigan; Veralox Therapeutics
- Class Amines; Antihyperglycaemics; Antithrombotics; Benzothiazoles; Small molecules; Sulfonamides
- Mechanism of Action 12-lipoxygenase inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heparin-induced thrombocytopenia and thrombosis syndrome
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 26 Sep 2023 Phase-II clinical trials in Heparin-induced thrombocytopenia and thrombosis syndrome (In adults) in USA (IV) (NCT05785819)
- 15 Jun 2023 Pharmacodynamics data from preclinical studies in Type I diabetes mellitus presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)
- 13 Jun 2022 Adverse events data from a phase Ia trial in healthy volunteers released by Veralox Therepeutics